Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Armandi

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Alimentary Pharmacology & Therapeutics|May 8, 2026
Editorial: Refining the Natural History of MASLD by Imaging-Based Markers: The GOLDMINE StudyFederico Perna, Angelo Armandi
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Natural history of NASHAngelo Armandi, Elisabetta Bugianesi
Clinics in Liver Disease|April 6, 2023
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Cardiovascular DiseasesAngelo Armandi, Elisabetta Bugianesi
European Journal of Internal Medicine|January 23, 2024
Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver diseaseAngelo Armandi, Elisabetta Bugianesi
Handbook of Experimental Pharmacology|November 23, 2021
NAFLD and NASH: The Metabolically Diseased LiverAngelo Armandi, Jörn M Schattenberg
Nutrients|July 2, 2021
Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary ApproachesAngelo Armandi, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|March 12, 2021
Editorial: the polygenic risk of cirrhosis developmentAngelo Armandi, Jörn M Schattenberg
Gut|August 8, 2020
NAFLD between genes and environment: what drives fibrogenesis?Angelo Armandi, Jörn M Schattenberg
Liver International : Official Journal of the International Association for the Study of the Liver|October 16, 2024
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLDSalvatore Petta, Angelo Armandi, Elisabetta Bugianesi
Minerva Gastroenterology|April 1, 2021
Tight junction regulation in celiac disease: role of larazotide acetateAngelo Armandi, Rinaldo Pellicano, Gian P Caviglia
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Alimentary Pharmacology & Therapeutics|May 8, 2026
Editorial: Refining the Natural History of MASLD by Imaging-Based Markers: The GOLDMINE StudyFederico Perna, Angelo Armandi
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Natural history of NASHAngelo Armandi, Elisabetta Bugianesi
Clinics in Liver Disease|April 6, 2023
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Cardiovascular DiseasesAngelo Armandi, Elisabetta Bugianesi
European Journal of Internal Medicine|January 23, 2024
Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver diseaseAngelo Armandi, Elisabetta Bugianesi
Handbook of Experimental Pharmacology|November 23, 2021
NAFLD and NASH: The Metabolically Diseased LiverAngelo Armandi, Jörn M Schattenberg
Nutrients|July 2, 2021
Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary ApproachesAngelo Armandi, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|March 12, 2021
Editorial: the polygenic risk of cirrhosis developmentAngelo Armandi, Jörn M Schattenberg
Gut|August 8, 2020
NAFLD between genes and environment: what drives fibrogenesis?Angelo Armandi, Jörn M Schattenberg
Liver International : Official Journal of the International Association for the Study of the Liver|October 16, 2024
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLDSalvatore Petta, Angelo Armandi, Elisabetta Bugianesi
Minerva Gastroenterology|April 1, 2021
Tight junction regulation in celiac disease: role of larazotide acetateAngelo Armandi, Rinaldo Pellicano, Gian P Caviglia
Pageof 13